A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis.
Our report discusses a 29 year old female patient with nephrotic syndrome due to lupus nephritis, biopsy-proven World Health Organization classification Types IVb and V that was controlled with low-density lipoprotein (LDL) apheresis. She was initially treated with steroid therapy, including methylprednisolone pulse therapy, and the serological activity of her systemic lupus erythematosus was suppressed. However, her nephrotic state, accompanied by severe hyperlipidemia, persisted despite the steroid therapy. Since we could not obtain her consent to administer immunosuppressants such as cyclophosphamide, we tried to treat her using LDL apheresis (LDL-A). We found that her urine protein excretion, hyperlipidemia, hypoalbuminemia, and renal function improved following the initiation of LDL-A. This suggests that LDL-A may be an effective therapy for nephrotic syndrome due to lupus nephritis through short-term amelioration of hyperlipidemia.
Kamijo
Yuji
Y
Second Department of Internal Medicine, Shinsu University School of Medicine, Matsumoto, Nagano, Japan.
Kaneko
Yoko
Y
Ichikawa
Toru
T
Kobayashi
Nobuhiko
N
Koyama
Takayuki
T
Kakegawa
Tetsuji
T
Kamijo
Hiroshi
H
Kono
Keiichi
K
Minami
Satoshi
S
Tanaka
Naoki
N
Arakura
Hideo
H
Hirata
Masayuki
M
Higuchi
Makoto
M
Kiyosawa
Kendo
K
Hora
Kazuhiko
K
D000328:Adult; D001781:Blood Component Removal; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008181:Lupus Nephritis / Q000150:complications*; D009404:Nephrotic Syndrome / Q000097:blood / Q000209:etiology / Q000628:therapy*
D008077:Lipoproteins, LDL